Abstract

Graft-versus-host disease (GVHD) prophylaxis often consists of calcineurin inhibitor-based combinations that indiscriminately curtail T cell receptor signal transduction. This broad inactivation consequently impairs the function of alloreactive pathogenic T cells as well as beneficial regulatory T cells (Treg) and anti-tumor cytotoxic T lymphocytes (CTL). Due to this non-selective approach, GVHD prevention is incomplete and the graft-versus-leukemia (GVL) effect is jeopardized. Disclosed are isolated binding molecules that disrupt the interaction of DLL4 and Notchl and methods of their use, including, but not limited to the treatment of graft versus host disease.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed are compositions comprising delta-tocotrienol and methods for using the same in the prevention of cancer progression. The methods comprise of reducing, inhibiting, decreasing, and/or preventing the progression of a neoplasm to a cancer (including, but not limited to lung cancer, ovarian cancer, breast cancer, rectal cancer, pancreatic, colon cancer, or intraductal papillary mucinous neoplasm (IPMN) to pancreatic ductal adenocarcinoma) in a subject comprising administering to a subject a therapeutically effective amount of a composition comprising delta-tocotrienol (d-T3).

IPC Classes  ?

• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• A61P 35/00 - Antineoplastic agents

Abstract

This disclosure describes processes for the asymmetric synthesis of trifunctionalized sulfur(VI) containing organic compounds of Formula I and Formula VI, as well as compounds of Formula I and Formula VI prepared by the processes described.

IPC Classes  ?

• C07C 311/15 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
• C07C 381/10 - Compounds containing sulfur atoms doubly-bound to nitrogen atoms
• C07C 311/16 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
• C07C 311/19 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
• C07D 277/36 - Sulfur atoms

Abstract

This invention relates to a transdiscal screw capable of following a non-linear trajectory. The screw assembly includes a first screw and second screw coupled at a poly-axial joint. The first screw and the second screw capable of rotating independently of each other. The screw can also include a third screw coupled to the second screw at a poly-axial joint such that the first screw, second screw and third screw can rotate independently of each other.

IPC Classes  ?

• A61B 17/86 - Pins or screws
• A61B 17/70 - Spinal positioners or stabilisers, e.g. stabilisers comprising fluid filler in an implant

Abstract

Disclosed are compositions and methods for gene transfer in immune effector cells, e.g. to create chimeric antigen receptors (CARs). In particular, polypeptides are disclosed that comprising an antigen-binding region and a heparin binding domain, wherein the antigen-binding region is capable of specifically binding to an immune cell antigen located on an immune effector cell, and wherein the heparin binding domain is capable of binding a viral vector.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

IPC Classes  ?

• C07K 5/117 - Tetrapeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp
• A61K 38/34 - Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 49/00 - Preparations for testing in vivo
• A61K 49/10 - Organic compounds
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/68 - Melanocyte-stimulating hormone [MSH]
• C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones

Abstract

Disclosed herein are chimeric antigen receptor (CAR) polypeptides, which can be used with adoptive cell transfer to target and kill cancers, that comprise a co-stimulatory signaling region having a mutated form of a cytoplasmic domain of CD28 for increased IL-2 production. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a tumor associated antigen-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Goods & Services

Downloadable cookbooks Printed cookbooks

Goods & Services

Downloadable cookbooks Printed cookbooks

Abstract

The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion. Microarray containing miRNAs indicative of the presence of pancreatic cancer, or having a high risk of pancreatic cancer development, particularly, in a subject having a pancreatic lesion, and methods of use of the microarrays are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Disclosed herein are dimeric or pentameric antigen binding molecules and methods for making said dimeric or pentameric antigen binding molecules, wherein the isotype of the immunoglobulin monomers is IgA, 1gG4, or IgM. Also disclosed herein are methods of using dimeric antigen binding molecules to treat cancer associated with expression of an oncogene, gene overexpression, or a gene fusion.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

A method and system for performing bone fusion and/or securing one or more bones, such as adjacent vertebra, are disclosed.

IPC Classes  ?

• A61F 2/44 - Joints for the spine, e.g. vertebrae, spinal discs
• A61F 2/30 - Joints

Abstract

Peptides useful as inflammasome inhibitors are disclosed and can comprise an H2 helix of a pyrin domain, wherein at least two non-consecutive amino acids of the H2 helix are covalently linked. Methods of treating a subject with a disease comprising administering to the subject the disclosed peptides are also disclosed. Further, disclosed herein are methods of inhibiting binding between a first polypeptide comprising a pyrin domain and a second polypeptide comprising a pyrin domain, the method comprising contacting either the first polypeptide or the second polypeptide with the disclosed peptides.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/00 - Medicinal preparations containing peptides

Goods & Services

Implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer; Pharmaceutical preparations for the treatment of cancer

Goods & Services

Implantable subcutaneous drug delivery devices sold filled with pharmaceutical preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer; Pharmaceutical preparations for the treatment of cancer

Goods & Services

Providing an on-line forum for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care. Recorded computer software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care. Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing on-line non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing a website featuring non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing temporary use of on-line non-downloadable software and applications using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing online non-downloadable computer software platforms for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care.

Goods & Services

Providing an on-line forum for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care. Recorded computer software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care. Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing on-line non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing a website featuring non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing temporary use of on-line non-downloadable software and applications using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing online non-downloadable computer software platforms for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care.

Goods & Services

Providing an on-line forum for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care. Recorded computer software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care. Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing on-line non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing a website featuring non-downloadable software using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing temporary use of on-line non-downloadable software and applications using artificial intelligence (AI) for building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research and patient care; Providing online non-downloadable computer software platforms for healthcare professional and computer scientists to interact, discuss and networking with the purpose and interest in building an open-source infrastructure to develop clinical language models and tools to advance generative AI and machine learning in medicine, medical research, and patient care.

Abstract

The present disclosure relates to systems and methods for the assessment of early adverse events (AE) to predict and improve a clinical outcome of a treatment regimen.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, bispecific antibodies are disclosed that are able to engage T-cells to destroy TAG-72-expressing malignant cells.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/46 - Hybrid immunoglobulins

Abstract

Disclosed herein is a system that addresses all of the current challenges described above by combining three existing technologies and an improved nuclear RNA delivery system to generate a first-in-class cellular therapy that can secrete a cancer specific suicide gene for the treatment of several cancers. Also disclosed herein is a 'Trojan-Horse' like genetic construct aimed at engineering a chemo-sensitive dominant clone for adaptive therapy in cancers, such as leukemia. In some embodiments, cells, such as cancer cells from a subject, are engineered with suicide genes to promote a bystander effect in neighboring cancer cells once returned to the subject. In some embodiments, these cells are further engineered to be clonally dominant, e.g. by deleting or mutating tumor suppressor genes in the cells, overexpressing oncogenes, or any combination thereof. Once the engineered cells have reached a target clonal dominance, the suicide gene can be induced, thereby promoting the bystander effect.

IPC Classes  ?

• C12N 5/0781 - B cellsProgenitors thereof
• C12N 15/86 - Viral vectors
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C07K 14/155 - Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 5/10 - Tetrapeptides

Abstract

Disclosed herein is an mRNA vaccine encoding a variant (double mutant form) of the survivin polypeptide and methods for treating a malignancy, such as myeloma, or for inducing an immune response, by administering the variant survivin mRNA vaccine. Also disclosed are methods for treating a malignancy using the disclosed mRNA vaccine.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group

Abstract

The recent development of immunotherapies has ushered in a new era of cancer treatment. These therapeutics have led to revolutionary breakthroughs; however, the efficacy has been modest and is often restricted to a subset of patients. Hence, identification of which cancer patients will benefit from immunotherapy is essential. Multiplex immunofluorescence (mIF) microscopy allows for the assessment and visualization of the tumor immune microenvironment (TIME).

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Disclosed is a method for treating a tumor in a subject that involves detecting in a biopsy sample from the subject reduced expression of a 12 Chemokine gene signature; and then administering to the subject a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. The method can further involve administering to the subject a therapeutically effective amount of a STING agonist. The method can further involve administering to the subject tumor infiltrating lymphocytes (TILs), such as HLAmatched TILs.

IPC Classes  ?

• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61P 35/00 - Antineoplastic agents
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The disclosure provides a method of treating or reducing the risk of developing an alloimmune condition or an autoimmune condition in a subject in need thereof. The method comprises (a) measuring CD83 in a population of immune cells from the subject, and (b) administering to the subject a CD83-targeted therapeutic.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 207/12 - Oxygen or sulfur atoms

Abstract

Disclosed are inhibitors for CDK12/13 and uses thereof. Methods of using the disclosed compounds to treat cancer are also disclosed.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Abstract

The present disclosure provides compounds which find use as ULK1 inhibitors and their use in the treatment of medical disorders, in particular disorders associated with abnormal cellular proliferation such as cancers.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Goods & Services

Conducting of business conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Conducting of educational conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Arranging and conducting of conferences in the field of healthcare, medical research, cancer care, life sciences, and education

Goods & Services

Conducting of business conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Conducting of educational conferences in the field of healthcare, medical research, cancer care, life sciences, and education; Arranging and conducting of conferences in the field of healthcare, medical research, cancer care, life sciences, and education

Abstract

A medical device and method to deliver a liquid solution to a patient's tissue. In particular a medical device that is an infusion device comprising a plurality of delivery tubes with varying lengths and internal diameters so that when the selected plurality of delivery tubes are implanted there is equal impedance to flow through each of the attached delivery tubes resulting in equal flow out of the delivery tubes to regions of interest in the patient's tissue. The plurality of delivery tubes may be attached to an infusion hub in a regular symmetrical pattern or an irregular asymmetrical pattern as required to deliver liquid solution to a plurality of regions of interest in the patient's tissue.

IPC Classes  ?

• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters

Abstract

Disclosed herein are chimeric antigen receptor (CAR) polypeptides, which can be used with adoptive cell transfer to target and kill cancers, that comprise a co-stimulatory signaling region having a mutated form of a cytoplasmic domain of DAP10 that enhances CAR-T cell function, e.g. by reducing CAR-T cell exhaustion. Also disclosed are immune effector cells, such as γδ T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a tumor associated antigen-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present disclosure provides inhibitors of the beta-catenin/B-cell lymphoma 9 interaction as well as their use in the treatment of oncological disorders. Further provided herein are methods of treating or preventing cancer in a subject, comprising administering to the subject an effective amount of a compound or composition as disclosed herein.

IPC Classes  ?

• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
• A61P 35/00 - Antineoplastic agents

Abstract

A method for slide image registration includes receiving slide images, detecting features contained in the slide images, comparing pairs of the slide images using the detected features, creating a distance matrix that reflects a respective difference between each of the pairs of the slide images, ordering the slide images to create a slide image series using the distance matrix, determining transformation matrices for registering the slide images, where a respective transformation matrix rigidly aligns a first slide image (Ii) to a second slide image (Ii−1), wherein i is the position of a slide image within the slide image series, and the respective transformation matrix that rigidly aligns the first and second slide images is determined using a set of the detected features shared by neighboring slide images in the slide images series, and rigidly aligning the slide images using the transformation matrices.

IPC Classes  ?

• G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
• G06V 10/74 - Image or video pattern matchingProximity measures in feature spaces
• G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks

Abstract

An example method for grading, segmenting, and analyzing lung adenocarcinoma (LUAD) pathology slides using artificial intelligence is described herein. The method includes receiving a digital pathology image of a LUAD tissue sample; inputting the digital pathology image into an artificial intelligence model; and grading, using the artificial intelligence model, the one or more tumors within the LUAD tissue sample.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation

Abstract

Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.

IPC Classes  ?

• C07D 207/416 - 2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
• C07D 211/84 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents

Abstract

An example method for predicting medical risk is described herein. The method includes receiving multi-modal health data for a subject, and inputting the multi-modal health data into a trained machine learning model. The method also includes predicting, using the trained machine learning model, a medical risk for the subject. The multi-modal health data for the subject includes patient-generated health data (PGHD), patient-reported outcome (PRO) data, and imaging data.

IPC Classes  ?

• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
• G16H 40/00 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices
• G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
• G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
• G06N 20/00 - Machine learning

Abstract

Disclosed are compositions and methods for targeted treatment of SSTR-expressing cancers. For example, disclosed herein are Bispecific T-Cell Engaging (BiTE) molecules (fusion polypeptides) (also referred to herein as bispecific molecules) that are able to crosslink CD3 complex on immune effector cells with SSTR2 on NETs. Also disclosed are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill SSTR-expressing cancers.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A device may obtain a magnetic resonance (MR) image of a region of interest (ROI) that includes at least a portion of the pancreatic lesion of the subject. A device may extract one or more radiomic features from the ROI of the MR image. A device may calculate a score from the one or more extracted radiomic features. A device may compare the score to a reference value. A device may classify the pancreatic lesion as malignant or benign based on the comparison.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G06T 7/45 - Analysis of texture based on statistical description of texture using co-occurrence matrix computation
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

Goods & Services

Medical educational services, namely conducting lectures, seminars and workshops in the field of health care, cancer care and prevention of cancer, autoimmunity, and medical diagnostics, prognostics and the evaluation of drug and treatment effectiveness relating to cancer and other autoimmune diseases. Medical research in the field of cancer and autoimmunity. Providing health care, medical information, and counseling in the field of cancer and autoimmunity; providing medical screening and diagnosis services with use of patient scanning equipment; medical services, namely, cancer care and prevention of cancer, and medical diagnostics, prognostics and evaluation of drug and treatment effectiveness relating to cancer and other autoimmune diseases.

Goods & Services

Medical educational services, namely conducting lectures, seminars and workshops in the field of health care, cancer care and prevention of cancer, autoimmunity, and medical diagnostics, prognostics and the evaluation of drug and treatment effectiveness relating to cancer and other autoimmune diseases. Medical research in the field of cancer and autoimmunity. Providing health care, medical information, and counseling in the field of cancer and autoimmunity; providing medical screening and diagnosis services with use of patient scanning equipment; medical services, namely, cancer care and prevention of cancer, and medical diagnostics, prognostics and evaluation of drug and treatment effectiveness relating to cancer and other autoimmune diseases.

Abstract

This present disclosure provides compounds which are useful in treating medical disorders. More particularly, compounds are provided for targeted degradation of TAF1 which are useful in the treatment of cancers.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems

Abstract

Disclosed herein is a method for enhancing adoptively transferred autologous or allogeneic immune effector T-cells (including gamma delta T cells (γδ-T cells)) by targeting the thioredoxin (TRX)-interacting protein (TXNIP). In addition, disclosed herein are cDNA sequences for the co-expression of immune receptors (CARs, TCRs, etc) in combination with guide RNAs, and/or artificial or natural microRNAs, and/or shRNAs targeting TXNIP.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors

Abstract

An Integrated Virtual Patient Framework (IVPF) for providing decision support that evolves with increasing data collected on a given patient. Support decisions for patients with limited data is made using statistical prediction tools derived from historical trajectories of similar patients. As patient histories grow, decision support is provided by mathematical models that constrain the possible dynamics of the patient to more detailed predictive models. Weights for each model are assigned depending on uncertainties arising from data fitting and model properties. As new data are entered into a patient record, the models are recalibrated and the weights are adjusted, leading to updated decision support information. The framework also suggests the benefit of additional follow-up data collection events, optimizing the data collection as well as how the IVPF generates predictions. The framework also may present scenarios to patients in a way that informs them of treatment outcomes, given various strategies.

IPC Classes  ?

• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G06Q 50/00 - Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

In one aspect, disclosed herein are novel CD40L monomers and methods of using said monomers, trimer constructs of said monomers, and or multimer constructs comprising said monomers for expanding tumor infiltrating lymphocytes (TILs) in vitro or ex vivo said methods comprising obtaining TILs and culturing the TILs in media comprising one or more CD40 agonists (such as, for example, a CD40 ligand (CD40L), a multimeric CD40L, and/or anti-CD40 antibody). In some aspects, the CD40 agonist can be overexpressed on a TIL, feeder cell.

IPC Classes  ?

• C07K 14/52 - CytokinesLymphokinesInterferons
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61P 35/00 - Antineoplastic agents

Goods & Services

Promoting the economic development of Pasco County in the State of Florida by coordinating academic, industry, and government research, education, clinical care delivery and entrepreneurship in the fields of healthcare, biotechnology, education, digital innovation, retail and commerce; business consulting services in the field of organizing partnerships between public and private entities; development of public-private partnerships for building shared research or manufacturing facilities, retail, and technology commercialization, namely, business networking, promoting collaboration within the scientific research and medical communities to achieve advances in the field of healthcare; operation services, namely, business management of services provided by others to maintain open spaces and parks; marketing services; communication services, namely, dissemination of advertising matter; public relations services; business management of property owners associations for others; property owner association services, namely, promoting the interests of property owners in a specific community and marketing the community nationwide to prospective new property owners; business management of tenant associations, namely, promoting the interests of real estate and commercial tenants in a specific community and marketing the community to the public and prospective new tenants; consultancy regarding public relations communication strategies; real estate sales management; providing a website featuring business information in the field of economic and workforce development, business, partnerships and networking, business collaboration services, and leasing and selling of retail and office spaces for business purposes, all designed to improve, market, promote and protect the shared real estate premises throughout the collaboration of the organization based there. Land leasing; leasing of real estate space, namely, office space, retail space, hotels and dormitories, apartments commercial space, laboratory and research space; land acquisition services; providing research scholarships; charitable fundraising; operation services, namely, rental property management and management of commercial property and offices; business collaboration services, namely, leasing and rental of offices and office space in the nature of a shared business environment consisting of conference rooms, classrooms and common gathering areas to entrepreneurs, start-ups, existing businesses, academic and research institutions and for the purpose of promoting collaboration to achieve benefits in business networking and business growth. Real estate development provided through public and private partnerships; real estate development services in the field of short-term residential, commercial, retail office, and industrial properties; real estate development services in the field of mixed use development comprised of residential, commercial, retail office, and industrial spaces; construction services, namely, construction planning, land development in the nature of planning and laying out of commercial, retail office and industrial buildings, building construction, space planning in the nature of laying out commercial, retail office and industrial buildings, laying out commercial, retail office and industrial buildings, building construction and construction management of park structures, open space structures, residential buildings, transportation buildings and commercial building projects. Educational services, namely, organizing events and conducting conferences in the field of innovation, health and medicine, agriculture and the environment, arts, architecture, business, communications, economic development, education, energy, engineering, humanities, and information science and technology for cultural or educational purposes. Hotel accommodation, restaurant, and bar services. Counseling services in the fields of nutrition, lifestyle wellness, and physical rehabilitation.

Goods & Services

Promoting the economic development of Pasco County in the State of Florida by coordinating academic, industry, and government research, education, clinical care delivery and entrepreneurship in the fields of healthcare, biotechnology, education, digital innovation, retail and commerce; business consulting services in the field of organizing partnerships between public and private entities; development of public-private partnerships for building shared research or manufacturing facilities, retail, and technology commercialization, namely, business networking, promoting collaboration within the scientific research and medical communities to achieve advances in the field of healthcare; operation services, namely, business management of services provided by others to maintain open spaces and parks; marketing services; communication services, namely, dissemination of advertising matter; public relations services; business management of property owners associations for others; property owner association services, namely, promoting the interests of property owners in a specific community and marketing the community nationwide to prospective new property owners; business management of tenant associations, namely, promoting the interests of real estate and commercial tenants in a specific community and marketing the community to the public and prospective new tenants; consultancy regarding public relations communication strategies; real estate sales management; providing a website featuring business information in the field of economic and workforce development, business, partnerships and networking, business collaboration services, and leasing and selling of retail and office spaces for business purposes, all designed to improve, market, promote and protect the shared real estate premises throughout the collaboration of the organization based there. Land leasing; leasing of real estate space, namely, office space, retail space, hotels and dormitories, apartments commercial space, laboratory and research space; land acquisition services; providing research scholarships; charitable fundraising; operation services, namely, rental property management and management of commercial property and offices; business collaboration services, namely, leasing and rental of offices and office space in the nature of a shared business environment consisting of conference rooms, classrooms and common gathering areas to entrepreneurs, start-ups, existing businesses, academic and research institutions and for the purpose of promoting collaboration to achieve benefits in business networking and business growth. Real estate development provided through public and private partnerships; real estate development services in the field of short-term residential, commercial, retail office, and industrial properties; real estate development services in the field of mixed use development comprised of residential, commercial, retail office, and industrial spaces; construction services, namely, construction planning, land development in the nature of planning and laying out of commercial, retail office and industrial buildings, building construction, space planning in the nature of laying out commercial, retail office and industrial buildings, laying out commercial, retail office and industrial buildings, building construction and construction management of park structures, open space structures, residential buildings, transportation buildings and commercial building projects. Educational services, namely, organizing events and conducting conferences in the field of innovation, health and medicine, agriculture and the environment, arts, architecture, business, communications, economic development, education, energy, engineering, humanities, and information science and technology for cultural or educational purposes. Hotel accommodation, restaurant, and bar services. Counseling services in the fields of nutrition, lifestyle wellness, and physical rehabilitation.

Abstract

An example system for training a subject to perform an MRI guided procedure includes a virtual reality (VR) headset; a sensor configured to detect respiration; and a controller operably coupled to the VR headset and the sensor, the controller including a processor and a memory, the memory having computer-executable instructions stored thereon that, when executed by the processor, causes the controller to display, on the VR headset, a view from a perspective of a subject lying on a magnetic resonance imaging (MRI) linear accelerator, where the view includes information for assisting the subject in breath-holding to localize a tumor in a desired position.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 5/08 - Measuring devices for evaluating the respiratory organs

Abstract

Disclosed are engineered isoforms of humanin and the humanin like 8, chimeric antigen receptor cells, engineered tumor infiltrating lymphocytes, and marrow infiltrating lymphocytes comprising said isoforms. Also disclosed are methods of using the engineered isoforms chimeric antigen receptor cells, engineered tumor infiltrating lymphocytes, and marrow infiltrating lymphocytes in methods of treating a neurodegenerative disease.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed are compositions and methods for the delivery of anti-cancer therapies in a manner to cross the blood brain barrier or across the blood-CSF barrier across the choroid plexus in the treatment of a cancer, metastasis, and/or cancer complication including, but not limited to Leptomeningeal disease (LMD).

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 9/08 - Solutions
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are compositions and methods for targeted treatment of CD33-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CD33-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CD33-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. Also disclosed are multivalent antibodies are disclosed that are able to engage T-cells to destroy CD33-expressing malignant cells.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/725 - T-cell receptors

Abstract

Disclosed are methods for detecting and treating cancers and, in particular, metastasis based on the fucosylation of polio virus receptor (PVR). Said methods can comprise the detection of the fucosylation of PVR; wherein an increase or the presence of fucosylated PVR indicates a cancer and/or metastasis. Also disclosed are methods of treating said cancer comprising administering to a subject an agent that inhibits PVR and an agent that increases fucosylation.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

Disclosed herein are compounds and methods for educing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible Treg. In certain aspects, disclosed are compounds of Formula I-V. Disclosed herein are compounds and methods for educing the risk of developing, preventing, or treating graft versus host disease (GVHD) in a subject. The compounds can concurrently block Aurora kinase A and JAK2 signal transduction which synergistically suppresses alloreactive human T-cells in vitro, prevents xenogeneic graft-versus-host disease without impairing anti-tumor responses, and promotes the development and suppressive potency of CD39+ inducible Treg. In certain aspects, disclosed are compounds of Formula I-V.

IPC Classes  ?

• C07D 239/48 - Two nitrogen atoms
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A ventilator device for co-ventilation of multiple patients may include an air tube splitter having an inlet, a plurality of outlets, and a plurality of branches each extending to a respective outlet, a plurality of valves coupled to the branches, a plurality of actuators coupled to the valves, and a controller in operable communication with the actuators. Each valve may be configured to be adjusted to regulate air flow through a respective branch. Each actuator may be configured to adjust a respective valve. The controller may be configured to receive a set of inspiratory pressure settings or tidal volume settings for the patients and independently control the actuators to adjust the valves based at least in part on the set of inspiratory pressure settings or tidal volume settings. The controller may employ time-multiplexing in controlling the actuators to adjust the valves for ventilating the patients at different times.

IPC Classes  ?

• A61M 16/20 - Valves specially adapted to medical respiratory devices
• A61M 16/08 - BellowsConnecting tubes

Abstract

This disclosure provides compounds useful for the treatment of medical disorders, such as cancers, and more particularly to degraders of helicases, such as Superfamily 3 (SF3) and Superfamily 6 (SF6) helicases.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 31/20 - Antivirals for DNA viruses
• A61P 35/00 - Antineoplastic agents
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Disclosed are compositions and methods for treating, inhibiting, reducing, decreasing, and/or preventing a cancer, microbial infection, recurrent cancer, or recurrent infection via Bcl11b inhibition.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

This disclosure provides compounds useful for the treatment of medical disorders, such as cancers, and more particularly to inhibitors of helicases, such as Superfamily 3 (SF3) and Superfamily 6 (SF6) helicases.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/33 - Heterocyclic compounds

Abstract

Disclosed are compositions and methods for targeted treatment of glioblastomas. In particular, bi-specific chimeric antigen receptor (CAR) T cells are disclosed that can be used with adoptive cell transfer to target and kill glioblastomas. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with glioblastomas that involves adoptive transfer of the disclosed bi-specific CAR T cells.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

Disclosed are compositions and methods related to the use of nitric oxide inhibitors to reduce resistance to immune checkpoint inhibitors. In one aspect, disclosed herein are methods of detecting elevated NO or nitration of proteins in a biological sample from a subject with a cancer, and administering an NO inhibitor to the subject where immune suppressive cells have elevated levels of NO or protein nitration.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61P 35/00 - Antineoplastic agents

Goods & Services

Conducting of business conferences in the field of biotechnology, medical research, medical science, cancer research, entrepreneurship, and venture capitalism and investment in life sciences; Conducting of educational conferences in the field of biotechnology, medical research, medical science, cancer research, entrepreneurship, and venture capitalism and investment in life sciences; Arranging and conducting of conferences in the field of biotechnology, medical research, medical science, cancer research, entrepreneurship, and venture capitalism and investment in life sciences

Abstract

Disclosed herein is a method for predicting the responsiveness of a subject to CD40 agonist therapy, such as agonist anti-CD40 therapy, that involves assaying a tumor sample from the subject for a 12 Chemokine gene signature demonstrating that the tumor comprises tertiary lymphoid structures containing B cells. Therefore, also disclosed herein is a method of treating tumors, such as solid tumors, in a subject that involves administering to the subject an effective amount of a composition comprising assaying a tumor sample from the subject for a 12 Chemokine gene signature demonstrating that the tumor comprises tertiary lymphoid structures (TLS) containing B cells, and treating the subject with CD40 agonist therapy, such an agonist anti-CD40 antibody.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Compositions and methods are disclosed for targeted treatment of lung cancer-derived metastatic brain tumors. In particular, tumor targeting agents comprising targeting peptides are disclosed that can target a payload, such as a therapeutic or diagnostic agent, to lung cancer-derived metastatic brain tumors. Chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill lung cancer-derived metastatic brain tumors.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• C07K 14/725 - T-cell receptors

Goods & Services

Entertainment services in the nature of live musical performances; Entertainment, namely, live performances by a musical band; Live performances by a musical group

Abstract

Disclosed are WEE1 inhibitors and their use in methods of inhibiting a WEE1 epigenetic activity or treating cancer having WEE1 epigenetic activity.

IPC Classes  ?

• C07D 333/38 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

Disclosed herein is a method for treating a tumor having a temperature sensitive p53 (ts p53) mutation in a subject in need thereof. The method involves first administering to the subject a therapeutically effective amount of a chemotherapeutic drug, then inducing moderate hypothermia in the tumor for a duration sufficient to activate the mutant p53 to enhance the efficacy of the drug.

IPC Classes  ?

• A61F 7/12 - Devices for heating or cooling internal body cavities
• A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body
• A61F 7/10 - Cooling bags, e.g. ice-bags
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed herein is an assay comprising a probe panel to detect the methylation status of 12 genes and one CPG site. Also disclosed herein are methods for using an oral wash and the probe panel to detect the presence of oropharyngeal cancer based on the methylation status of the genes and the CPG site.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 40/20 - Supervised data analysis
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 50/30 - Data warehousingComputing architectures

Abstract

The present application relates to high flow rate isolated regional treatment of cancer and proliferative disorders and conditions. For example, provided are methods, systems and devices for treating a cancer in a region of a subject using high flow rate isolated infusion.

IPC Classes  ?

• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
• A61M 5/44 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for cooling or heating the devices or media

Abstract

Provided are compositions and methods for prophylaxis or therapy of cancer. The compositions comprise α-type-1 dendritic cells that have been treated with intact proteins that comprise cancer antigens, or peptides that comprise cancer antigens, or combinations thereof. The approaches can also include adding a chemokine-modulating regimen.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 31/415 - 1,2-Diazoles
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0784 - Dendritic cellsProgenitors thereof

Abstract

Disclosed are compositions and methods for targeted treatment of myeloid and B cell malignancies. In particular, chimeric antigen receptor (CAR) T cells are disclosed that can be used with adoptive cell transfer to target and kill myeloid and B cell malignancies with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a myeloid and B cell malignancies that involves adoptive transfer of the disclosed CAR T cells.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed are compositions and methods for targeted treatment of CD99-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CD99-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CD99-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. Also disclosed are multivalent antibodies are disclosed that are able to engage T-cells to destroy CD99-expressing malignant cells.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed are XBP-1/IRE-1 inhibitors having formula disclosed herein. Methods of making and using these inhibitors for the treatment of cancer, in particular B cell cancers, are also disclosed. Also disclosed is a genetic XBP-1-knockout cancer mouse model.

IPC Classes  ?

• C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
• A01K 67/0276 - Knock-out vertebrates
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 33/243 - PlatinumCompounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 311/18 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Abstract

Various implementations include a gas delivery and monitoring apparatus. The apparatus includes a support member, a bite block, a first elongated conduit, a second elongated conduit, and a bridge. The bite block has a lingual side extending between a first and a second side of the bite block. The first elongated conduit defines an exhalation capture flow path terminating in an elongated slot defined by the lingual side of the bite block that extends in a direction from the first side to the second side of the bite block. The second elongated conduit defines a gas delivery flow path terminating in a gas delivery port. Both the gas delivery port and capture inlet are located in the mouth of the subject when the bite block is inserted in the mouth of the subject during use. The bridge extends between the bite block and the support member.

IPC Classes  ?

• A61M 16/01 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes specially adapted for anaesthetising
• A61B 90/16 - Bite blocks
• A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices
• A61M 16/06 - Respiratory or anaesthetic masks

Abstract

A method and system for performing bone fusion and/or securing one or more bones, such as adjacent vertebra, are disclosed. The screws include a threaded tip connected to a main shaft and a threaded outer sleeve that rotates relative to the outer shaft until locked down. Independent rotation of the threaded outer sleeve relative to the threaded distal tip allows compression or distraction to modify the gap between the vertebral bodies. The screws are passed from the inferior to superior vertebra or superior to inferior, for example, through a trans-pedicular route to avoid neurological compromise. At the same time, the path of screw insertion is oriented to reach superior or inferior vertebra. An intervertebral cage of the system is configured for lateral expansion from a nearly straight configuration to form a large footprint in the disc space. The screws and cage may be combined for improved fixation with minimal invasiveness.

IPC Classes  ?

• A61B 17/86 - Pins or screws
• A61B 17/70 - Spinal positioners or stabilisers, e.g. stabilisers comprising fluid filler in an implant
• A61F 2/28 - Bones
• A61F 2/30 - Joints
• A61F 2/44 - Joints for the spine, e.g. vertebrae, spinal discs

Goods & Services

Sweat towels T-shirts; Shirts; Clothing jackets; Head bands Hand fans Tumblers for use as drinking glasses

Goods & Services

Sweat towels being textile workout towels T-shirts; Shirts; Clothing jackets; Headbands Fans for personal use, non-electric Tumblers for use as drinking glasses

Abstract

As disclosed herein, high expression of the inhibitory ligands Galectin-3 (LAG-3 ligand), Galectin-9 (Tim-3 ligand), HMGB1 (Tim-3 ligand), CD112 (CD112R ligand) and TNFSF10 (DR5 ligand) in the microenvironment of triple negative breast cancer cells is inhibitory for T-cells. Therefore, disclosed herein is a chimeric receptor comprising an extracellular domain of TIM-3, LAG-3, CD112R or DR5 and transmembrane and intracellular domain of a pro-inflammatory interleukin and/or a co-stimulatory domain. Also disclosed is an immune effector cell engineered to express a chimeric antigen receptor (CAR) polypeptide and the disclosed chimeric receptor. Also disclosed is a method of providing an anti-cancer immunity in a subject with a MUC1-expressing cancer, the method comprising administering to the subject an effective amount of the disclosed immune effector cell, thereby providing an anti-tumor immunity in the subject.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/54 - Interleukins [IL]
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

Disclosed novel expression and mutation patterns that correlate with the presence of a malignancy in B and T cell cancers. Accordingly, disclosed herein are kits and methods for the diagnosis of cancer malignancies.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/415 - 1,2-Diazoles
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Disclosed are methods for the detection and isolation of disseminated cancer cells and the used of tumor antigen pulsed type 1 dendritic cell vaccine for the treatment and prevention of metastasis and abscopal tumors.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed are combination therapies comprising a semaphoring vaccine and dendritic cell vaccine and methods of their use in the treatment of cancer.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C12N 5/0784 - Dendritic cellsProgenitors thereof

Abstract

Bi-specific CAR-T cells are disclosed for treating NSCLCs. The disclosed CAR-T cells contain CAR polypeptides that can bind EGFR/MUC1-expressing cells. Therefore, also disclosed is an immune effector cell genetically modified to express an anti-EGFR CAR binding agent and an anti-MUC1 binding agent. Also disclosed are methods of providing an anti-tumor immunity in a subject with a EGFR and MVUC1-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

Disclosed are methods for treating, inhibiting, reducing, and/or preventing cancers (such as, for example melanoma) and/or metastasis (such as, for example metastatic melanoma) comprising administering to a subject a L-fucose and an anti-androgen therapy.

IPC Classes  ?

• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 38/09 - Luteinising hormone-releasing hormone [LHRH]Related peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer having endodomains with a customized number of immunoreceptor tyrosine-based activation motifs (ITAMs). In some embodiments, the endodomain has a backbone of a receptor endodomain, such as CD8, CD3ζ, CD3δ, CD3γ, CD3ϵ, CD32 (Fc gamma RIIa), DAP10, DAP12, CD79a, CD79b, FcγRIγ, FcγRIIIγ, FcϵRIβ (FCERIB), and FcϵRIγ (FCERIG). In particular embodiments disclosed herein, the backbone is a DAP12 backbone. The disclosed endodomain is engineered to express at least one heterologous ITAM, including 1, 2, 3, 4, 5, or 6 ITAMs.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 14/735 - Fc receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

Disclosed herein is a method for treating a solid tumor in a subject that involves assaying a sample from the subject for expression of two or more Histone deacetylases (HDACs); determining a response score from the expression of the two or more HDACs, wherein the response score predicts whether the subject will respond to combination immunotherapy and HDAC inhibitor therapy; and administering to the subject a therapeutically effective amount of a combination of immunotherapy and an HDAC inhibitor.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

This disclosure provides compounds useful for treating medical disorder, and more particularly ACK1 inhibitors useful for treating cancers.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings

Abstract

As disclosed herein, the cytoplasmic mitochondria and proteins can invade into the nucleus of cancer cells in the context of constitutive viral response cluster activation or overexpression. While this can be very dynamic process with a rapid invasion versus retraction cycles resulting in relatively complete nuclear and cytoplasmic compartmentalization, compositions and methods are provided to detect nuclear invasion of cytoplasm (NiC) and cytoplasmic mitochondria (NiCM) by inhibiting kinases that regulate influx and efflux of cargoes in and out of NiC. An RNA probe was developed which labels mitochondria when conjugated to a fluorochrome and is a part of NiCM detection.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61P 35/00 - Antineoplastic agents

Goods & Services

Printed publications, namely printed teaching materials, brochures in the field of cancer care and prevention of cancer, and autoimmunity; Printed pamphlets, bulletins, newsletters and magazines in the field of cancer care and prevention of cancer, and autoimmunity Medical educational services, namely conducting lectures, seminars and workshops in the field of health care, cancer care and prevention of cancer, autoimmunity, and medical diagnostics, prognostics and the evaluation of drug and treatment effectiveness relating to cancer and other autoimmune diseases Medical research in the field of cancer and autoimmunity Providing health care, medical information, and counseling in the field of cancer and autoimmunity; providing medical screening and diagnosis services with use of patient scanning equipment; medical services, namely, cancer care and prevention of cancer, and medical diagnostics, prognostics and evaluation of drug and treatment effectiveness relating to cancer and other autoimmune diseases

Abstract

Disclosed are novel HPV E6 and HPV E7 binding molecules and methods of their use in the treatment of HPV and cancers resulting from an HPV infection.

IPC Classes  ?

• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/20 - Antivirals for DNA viruses

Abstract

Clinical testing to identify targeted therapies is frequently performed with next generation sequencing (NGS). Clinical action and trial enrollment is often based on expected associations of gene changes with protein expression or action. However, comprehensive RNA and protein expression is not routinely performed in the clinical repertoire of testing clinical tumor samples. The relationship between genetic changes, including gene amplification, with increased RNA and protein expression in the context of clinical testing remains poorly understood. What are needed are new methods of identifying targets that account for both genomic and proteomic information. Disclosed are novel RNA and protein expression panels and methods of using said panels for the detection of cancer and determining the suitability of a subject for a treatment regimen or clinical trial.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Tumor infiltrating lymphocytes (TILs) are immune cells that have left the bloodstream and migrated into a tumor. TILs have been used in autologous adoptive transfer therapy for the treatment of cancer. Disclosed are methods for rapidly expanding tumor infiltrating lymphocytes using digested tumor cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61P 35/00 - Antineoplastic agents
• C12N 5/0781 - B cellsProgenitors thereof

Abstract

Described herein are small molecule inhibitors of the β-catenin/B-cell lymphoma 9 interaction and pharmaceutical compositions including a therapeutically effective amount of the small molecule inhibitors described herein. Described are also methods of treating oncological disorders, for example cancer by administering the small molecule inhibitors of the β-catenin/B-cell lymphoma interaction described herein.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61P 35/00 - Antineoplastic agents
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/10 - Spiro-condensed systems
• C07D 487/04 - Ortho-condensed systems

Abstract

Disclosed are TATE derivatives having a linker between the TATE moiety and a macrocyclic radionuclide chelating moiety. Methods of synthesis and use are also disclosed. The compounds preferably exhibit a ratio of kidney: liver uptake by a subject within 24 hours of 5 or less, 3 or less, 1 or less, 0.5 or less, preferably from 2:1 to 1:2.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are methods for treating a cancer and/or enhancing immune responses to infiltration of tumors comprising administering to a subject a fucose. Also disclosed herein are methods of detecting the presence of a sugar-modified protein (i.e., a glycosylated protein).

IPC Classes  ?

• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12Q 1/686 - Polymerase chain reaction [PCR]
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to suppress alloreactive donor cells. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed regulatory T cells engineered to express the disclosed CARs. Also disclosed is a method of preventing rejection of off-the-shelf therapeutic immune effector cells, such as CAR-T cells, in a subject that involves administering to the subject an effective amount of a regulatory T cell genetically modified with a disclosed CD83-specific CAR.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed are methods for treating infectious diseases and cancers comprising administering to a subject a L-fucose.

IPC Classes  ?

• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are methods for identifying a gene regulatory network and treatment regimens combined with MM standard of care drugs to either delay, or reverse resistance to the standard of care therapy. Also disclosed is a synergy between Selinexor (SELI) and dexamethasone (DEX), pomalidomide (POM), elotuzumab (ELO), and daratumumab (DARA), and expression signatures and mutations associated with response to these agents.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 40/20 - Supervised data analysis
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

Disclosed are prodrugs of temozolomide (TMZ) of Formula I and Formula II that can have increased solubility and/or increased permeability across the blood brain barrier as compared to TMZ. Methods of making and using the disclosed prodrugs are also described.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/33 - Heterocyclic compounds

Abstract

A method of processing medical image data to predict disease progression in non-small cell lung cancer (NSCLC) patients includes receiving a multiplexed tissue image comprising a plurality of cells stained for one or more markers, evaluating the multiplexed tissue image using a machine learning model, and predicting whether a patient's NSCLC will progress based on the evaluation of the multiplexed tissue image using the machine learning model.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 5/70 - DenoisingSmoothing
• G06T 7/11 - Region-based segmentation
• G06T 7/136 - SegmentationEdge detection involving thresholding
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

Disclosed herein are methods for identifying patients at risk for severe immune-related adverse events before the start of immunotherapy, which can optimize patient management and treatment planning and alleviate future complications with early interventions. This can involve analyzing 18F-FDG PET/CT images of a patient to determine PET features, CT features, and Kulbek Leibler Divergence (KLD) features from KLD images generated from the PET and CT images based upon KLD criteria,and computing a modified radiomic score (MRS) based on the radiomic signature that is predictive of severe immune-related adverse events in the patient.

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• G06T 7/00 - Image analysis
• G06T 7/45 - Analysis of texture based on statistical description of texture using co-occurrence matrix computation
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/48 - NMR imaging systems
• G01T 1/16 - Measuring radiation intensity
• G06N 3/02 - Neural networks
• G01T 1/29 - Measurement performed on radiation beams, e.g. position or section of the beamMeasurement of spatial distribution of radiation

Goods & Services

Publications, namely, printed instructional and teaching materials, brochures, pamphlets, bulletins, newsletters and magazines, all in the field of health care, cancer protection, prevention, detection and treatment, medical diagnostics and prognostics and the evaluation and testing of drug and treatment effectiveness relating to cancer and other diseases.

Abstract

Disclosed herein are methods of providing an anti-tumor immunity in a subject with a CD83-expressing cancer that involves adoptive transfer of the immune effector cells engineered to express chimeric antigen receptor (CAR) polypeptides that selectively bind CD83-expressing cancers. Also disclosed herein are dual-CAR systems to increase safety and/or efficacy of the CAR-T cells.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants